Targeting IRS-1/2 in uveal melanoma inhibits in vitro cell growth, survival and migration, and in vivo tumor growth.
Chattopadhyay, C.; Bhattacharya, R.; Roszik, J.; Khan, F.; Wells, G. A.; Villanueva, H.; Qin, Y.; Bhattacharya, R.; Patel, S.; Grimm, E. A.
Show abstract
Uveal melanoma (UM) originating in the eye and metastasizing to the liver is associated with poor prognosis and has only one approved therapeutic option. We hypothesized that liver-borne growth factors may contribute to UM growth. Therefore, we investigated the role of insulin-like growth factor -1 and its receptor (IGF-1/IGF-1R) signaling in UM. We found that the insulin receptor substrate -1 (IRS-1) is overexpressed in UM cells and tumors. Since we previously observed that IGF-1R antibody therapy was not clinically effective in UM, we investigated the potential of NT157, a small molecule inhibitor of IRS-1/2 in blocking this pathway in UM. NT157 treatment in UM cells resulted in reduced cell survival and migration, and increased apoptosis. This treatment also significantly inhibited UM tumor growth in vivo, in the chicken egg chorioallantoic membrane (CAM) and subcutaneous mouse models, validating the in vitro effect. Mechanistically, through reverse phase protein array (RPPA), we identified significant proteomic changes in the PI3K/AKT pathway, a downstream mediator of IGF-1 signaling, with NT157 treatment. Together, these results suggest that NT157 inhibits cell survival, migration in vitro and tumor growth in vivo via inhibiting IGF-1 signaling in UM.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Evaluation of deacetylase inhibition in metaplastic breast carcinoma using multiple derivations of preclinical models of a new patient-derived tumor 96%
- Preclinical assessment of MAGMAS inhibitor as a potential therapy for pediatric medulloblastoma 95%
- Blockade of Interleukin-6 (IL-6) Signaling in Dedifferentiated Liposarcoma (DDLPS) Decreases Mouse Double Minute 2 (MDM2) Oncogenicity via Alternative Splicing 95%
Similar papers in this journal
- Matched three-dimensional organoids and two-dimensional cell lines of melanoma brain metastases mirror response to targeted molecular therapy 94%
- Establishment and characterization of a cell line and patient-derived xenograft (PDX) from peritoneal metastasis of low-grade serous ovarian carcinoma 94%
- Periostin facilitates ovarian cancer recurrence by enhancing cancer stemness 94%
Similar papers in this journal
- The MEK1/2 pathway as a therapeutic target in high-grade serous ovarian carcinoma 95%
- Epigenetic Modulation of SPCA2 Reverses Epithelial to Mesenchymal Transition in Breast Cancer Cells 94%
- Suppression of Ovarian Cancer Cell Proliferation is Associated with Upregulation of Cell-Matrix Adhesion Programs and Integrin-β4-Induced Cell Protection from Cisplatin. 94%
Similar papers in this journal
- Downregulation of NCL attenuates tumor formation and growth in cervical cancer by targeting the PI3K/AKT pathway 93%
- Detecting PI3K and TP53 Pathway Disruptions in Early-Onset Colorectal Cancer Among Hispanic/Latino Patients 92%
- Circulating serum miRNAs predict response to platinum chemotherapy in high-grade serous ovarian cancer 91%
Similar papers in this journal
- Down-regulation of AKT proteins slows the growth of mutant-KRAS pancreatic tumors 95%
- RUNX1 is regulated by androgen receptor to promote cancer stem markers and chemotherapy resistance in triple negative breast cancer. 94%
- FGF9, a potent mitogen, is a new ligand for integrin αvβ3, and the FGF9 mutant defective in integrin binding acts as an antagonist. 93%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.